SI
VYNE icon

Sofinnova Investments’s VYNE Therapeutics VYNE Stock Holding History

Sofinnova Investments’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,077
Closed -$1.26M – 87
2020
Q2 		$1.26M Buy
10,077
+1,677
+20% +$227K 0.08% 68
2020
Q1 		$1.62M Buy
+8,400
New +$2.63M 0.15% 57

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments's VYNE Position: Q3 2020 in Review

Sofinnova Investments sold out of VYNE Therapeutics (VYNE) in Q3 2020, closing a stake of 10,077 shares — an estimated $1.26M sold.

Sofinnova Investments first reported a position in VYNE in Q1 2020 and held it in 2 quarters. The position peaked at $1.62M in Q1 2020. 105 funds tracked by Wall St. Rank hold VYNE as of Q3 2020.

  • Sofinnova Investments reported no remaining VYNE Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Sofinnova Investments sold 10,077 VYNE Therapeutics shares in Q3 2020, an estimated $1.26M.
  • Sofinnova Investments first reported a position in VYNE Therapeutics in Q1 2020 and held it in 2 quarters.
  • Sofinnova Investments's VYNE Therapeutics position peaked at $1.62M in Q1 2020.
  • 105 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2020.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.